High-Grade Endometrial Stromal Sarcoma after Tamoxifen Therapy for Breast Cancer

2005 ◽  
Vol 60 (2) ◽  
pp. 117-120 ◽  
Author(s):  
Francesco Sesti ◽  
Lodovico Patrizi ◽  
Beatrice Ermini ◽  
Giampiero Palmieri ◽  
Augusto Orlandi ◽  
...  
2003 ◽  
Vol 13 (5) ◽  
pp. 690-692 ◽  
Author(s):  
Y. Saga ◽  
M. Ohwada ◽  
T. Kohno ◽  
N. Takayashiki ◽  
M. Suzuki

Tamoxifen has been widely used in breast cancer treatment. In recent years, the occurrence of uterine malignancies in patients receiving long-term tamoxifen therapy has attracted attention. Most of these malignancies are endometrial adenocarcinomas, but low-grade endometrial stromal sarcomas have occasionally been reported. Here we report a woman who developed a high-grade endometrial stromal sarcoma after receiving postmastectomy tamoxifen therapy. The patient underwent a left mastectomy at age 45 and subsequently received oral tamoxifen for 3 years. At age 51, she was diagnosed with endometrial stromal sarcoma, for which a radical hysterectomy was performed. High-grade endometrial stromal sarcoma was diagnosed by postoperative histologic examination. Immunostaining for the estrogen receptor was negative in sarcoma cells, but positive in the residual endometrial epithelium and the nucleus of adjacent stromal cells within the tumor. The patient has now survived disease-free for 37 months after surgery.


Author(s):  
Pavneet Kohli ◽  
Prasanth Penumadu ◽  
Neelesh Srivastava ◽  
Bheemanathi Hanuman Srinivas ◽  
Vidyalakshmi Rangarajan

2012 ◽  
Vol 39 (1) ◽  
pp. 424-429 ◽  
Author(s):  
Tomoko Kashiyama ◽  
Katsutoshi Oda ◽  
Kei Kawana ◽  
Takahide Arimoto ◽  
Yukiko Kanetaka ◽  
...  

2021 ◽  
Author(s):  
Kimberly Dessources ◽  
Kathryn M. Miller ◽  
Elizabeth Kertowidjojo ◽  
Arnaud Da Cruz Paula ◽  
Youran Zou ◽  
...  

2016 ◽  
Vol 14 (2) ◽  
pp. 47-57
Author(s):  
Ekaterina P Fadeeva ◽  
Alla S Lisyanskaya ◽  
Georgiy M Manikhas ◽  
Ruslan I Glushakov ◽  
Natalia I Tapilskaya

This review provides the current evidence of clinical studies on the effectiveness of endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal sarcoma, by aromatase inhibitor (AI) III generation. The review presents dates from clinical trials comparing the effectiveness of AI and tamoxifen, as well as dates on combination therapy AI with inhibitors of mTOR pathway (BOLERO-2 trial), an antiestrogen (SWOG S0226, FACT, FIRST trials), an inhibitor of CDK4 / 6 (PALOMA -1 trial) and other drugs.


Sign in / Sign up

Export Citation Format

Share Document